The accidental sex drug
Melanotan II was developed at the University of Arizona in the 1980s and 1990s as part of an effort to create a safe tanning agent — a peptide that would stimulate melanin production without UV radiation, potentially reducing skin cancer risk. Researchers Mac Hadley and Victor Hruby synthesised a cyclic analogue of α-melanocyte stimulating hormone (α-MSH) that was more potent and more stable than the natural peptide.
The defining moment in its history came when one of the researchers self-injected the compound at twice the intended dose and experienced an eight-hour erection alongside nausea and vomiting. This accidental discovery redirected the research programme — one branch continued as the tanning peptide (eventually becoming afamelanotide, which is FDA-approved under the name Scenesse for erythropoietic protoporphyria) and another became PT-141/bremelanotide (FDA-approved as Vyleesi for HSDD).
Melanotan II itself was never developed into an approved drug — Clinuvel Pharmaceuticals abandoned this pursuit due to regulatory concerns and the non-selective receptor profile. Instead, it has circulated as an unregulated compound sold online and through gym networks for decades. It became known as the "Barbie drug" in the UK press due to its tanning and appetite-suppressing effects. Regulatory agencies in multiple countries have issued warnings against its use.
Critical regulatory status: Melanotan II is not approved anywhere. It is not the same as afamelanotide (Scenesse) or bremelanotide (Vyleesi) — both of which are FDA-approved products from the same research lineage. Melanotan II is sold unregulated, unverified, and untested for purity or dosing accuracy. The compounds sold online are frequently mislabelled, contaminated, or of unknown composition.
Non-selective — all five receptors
Mechanism of Action
What people report
"The tan is genuinely impressive — I look like I've been on holiday for two weeks after 10 doses with minimal sun. The erections are a real side effect — not unpleasant but inconvenient at times. The nausea the first few times was significant. Moles have darkened noticeably which concerns me."
Male, 34, UK, using Melanotan II purchased online. The mole darkening is the most clinically important observation — representing melanocyte activation in existing nevi. All users who notice mole changes should be seen by a dermatologist before continuing use.
"Used it for 3 years seasonally for tanning before I read more carefully about the melanoma cases. Switched entirely to PT-141 for the sexual function benefits — same mechanism, FDA approved, actual dosing accuracy. Haven't looked back."
Female, 38, switched from Melanotan II to bremelanotide (PT-141). This transition — from unregulated MT-II to the FDA-approved derivative — reflects a growing awareness in the informed community that bremelanotide provides the sexual function benefits of MT-II without the tanning risks and with reliable dosing.
What the data shows
Risks & considerations
⚠ Key Warnings
If using — risk reduction
Given the safety profile, this section focuses on harm reduction rather than enhancement. If someone chooses to use Melanotan II despite the risks, these measures reduce the most serious hazards.
Disclaimer: This section is provided as harm reduction information only. The editors do not recommend Melanotan II use. The safer, approved alternatives (PT-141 for sexual function, afamelanotide for light-sensitivity conditions) should be strongly preferred.
Editor's summary
Melanotan II occupies a unique position in this book: it is the only entry where the honest recommendation is to use the approved derivative instead. The sexual function effects are real — and they are available more safely and reliably through PT-141 (bremelanotide/Vyleesi). The tanning effects are real — and they are available through natural UV exposure with appropriate sun protection.
The melanoma risk is the genuinely unresolved question. The current evidence suggests the association with melanoma may reflect UV-seeking behaviour in users rather than direct carcinogenic activity of the peptide itself. But "may not cause melanoma" is a deeply unsatisfying safety conclusion for an unregulated compound with no dosing verification, and five published melanoma cases among a community that doesn't report systematically.
The community will continue using Melanotan II — the tanning and sexual effects are compelling and the knowledge of PT-141 as an alternative is not universal. For anyone reading this: PT-141 for sexual function, sun protection for tanning, and a dermatologist before any melanocortin compound.